efficaci
studi
femal
hors
time
hous
singl
pen
condit
meet
victorian
bureau
anim
welfar
code
practic
welfar
hors
wwwdpivicgovauagricultureaboutagriculturelegislationregulationanimalwelfarelegislationcodesofpracticeanimalwelfarecodewelfareofhors
one
side
pen
abl
move
toward
hors
ratchet
mechan
allow
staff
close
access
hors
requir
side
pen
without
need
enter
pen
room
temperatur
maintain
air
changesh
humid
rang
hors
fed
mixtur
lucern
alfalfa
grass
hay
concentr
specifi
fruit
veget
day
hev
exposur
indwel
jugular
cathet
sutur
posit
intrauterin
temperatur
datalogg
place
hors
vaccin
hors
euthan
elect
day
challeng
unvaccin
hors
euthan
upon
reach
predetermin
human
endpoint
day
vaccin
human
end
point
defin
fever
h
accompani
increas
respiratori
rate
dyspnea
depress
ataxia
press
head
side
stall
euthanasia
conduct
intraven
inject
barbitur
follow
sedat
intraven
detomidin
butorphanol
ferret
guinea
pig
use
control
efficaci
studi
confirm
pathogen
inoculum
hous
pair
facil
given
speciesappropri
dri
ration
dietari
treat
provid
water
ad
libitum
viru
challeng
sampl
immobil
intramuscular
inject
mixtur
ketamin
hydrochlorid
mgkg
medetomidin
gkg
effect
medetomidin
revers
intramuscular
inject
atipemazol
gkg
anim
room
staff
wore
fulli
encapsul
suit
extern
air
suppli
appropri
anim
studi
endors
csiro
australian
anim
health
laboratori
anim
ethic
committe
andor
commonwealth
serum
laboratori
zoeti
anim
ethic
committe
work
use
gammairradi
hev
solubl
g
hevsg
glycoprotein
produc
chines
hamster
ovari
cho
cell
done
australian
quarantin
inspect
servic
vivo
permit
number
work
use
hevsg
glycoprotein
produc
human
embryon
kidney
done
australian
quarantin
inspect
servic
vivo
permit
number
clinic
trial
conduct
australian
pesticid
veterinari
medicin
author
research
permit
per
per
per
per
subunit
vaccin
contain
recombin
hevsg
glycoprotein
formul
proprietari
adjuv
zoeti
vaccin
formul
hevsg
glycoprotein
produc
use
chines
hamster
ovari
cho
human
embryon
kidney
cell
express
system
differ
hevsg
glycoprotein
prepar
affinitypurifi
sg
glycoprotein
cell
clarifi
sg
contain
cell
cultur
supernat
cho
cell
vaccin
initi
efficaci
studi
target
speci
formul
affinitypurifi
sg
glycoprotein
subsequ
vaccin
formul
clarifi
cho
cell
cultur
supernat
gamma
irradi
chang
express
system
cell
cho
cell
driven
need
higher
antigen
yield
equival
support
laboratori
analysi
express
antigen
system
comparison
studi
ferret
vaccin
formul
use
efficaci
studi
summar
tabl
immun
compris
two
dose
administ
intramuscularli
week
apart
unless
state
otherwis
efficaci
studi
hors
receiv
vaccin
contain
hevsg
glycoproteindos
hors
receiv
hevsg
glycoproteindos
tabl
hors
efficaci
studi
expos
oronas
tissu
cultur
infecti
dose
lowpassag
hev
isol
hendra
hors
challeng
day
second
vaccin
hors
challeng
day
second
vaccin
hors
select
vaccin
hors
larger
field
efficaci
safeti
studi
basi
tempera
lowest
serum
neutral
titer
group
time
overal
efficaci
test
complet
vaccin
hors
use
first
test
use
second
use
third
use
fourth
test
pathogen
control
inoculum
provid
hors
test
guinea
pig
test
ferret
test
ferret
test
guinea
pig
ferret
receiv
tissu
cultur
infecti
dose
viru
prepar
use
hors
guinea
pig
receiv
dose
intraperiton
inject
ferret
receiv
dose
oronas
rout
experi
shown
dose
rout
administr
expect
lethal
guinea
pig
ferret
exposur
condit
addit
unvaccin
control
hors
equival
use
vaccin
hors
inoculumcontrol
hors
describ
efficaci
studi
nasal
oral
rectal
swab
sampl
urin
fece
sampl
blood
sampl
edta
collect
hors
viru
exposur
daili
anim
euthan
swab
sampl
collect
duplic
ml
phosphatebuff
salin
viru
isol
magmax
lysisbind
solut
ambion
austin
tx
usa
rna
extract
urin
edta
blood
sampl
fluid
ad
lysisbind
solut
postmortem
examin
follow
tissu
collect
viral
genom
detect
viru
isol
histopatholog
immunohistochemistri
accord
adren
gland
bladder
brain
includ
olfactori
pole
cerebrospin
fluid
guttur
pouch
heart
kidney
larg
intestin
liver
lung
lymph
node
bronchial
inguin
intermandibular
mandibular
renal
mening
nasal
turbin
ovari
pharynx
small
intestin
spinal
cord
spleen
sympathet
nerv
trigemin
ganglion
uteru
follow
analys
conduct
describ
quantit
revers
transcript
pcr
detect
hev
n
gene
histolog
immunohistolog
serum
neutral
test
viru
isol
vaccin
efficaci
immun
hors
assess
clinic
virolog
patholog
featur
hev
infect
unvaccin
control
hors
infect
characterist
unvaccin
anim
describ
data
fourth
control
anim
gather
part
current
work
fourth
control
onset
fever
accompani
rise
heart
rate
note
postchalleng
day
postchalleng
day
hors
becam
clinic
depress
temperatur
heart
rate
continu
rise
euthan
gross
postmortem
find
includ
pleural
thicken
moder
dilat
lymphat
vessel
ventral
cm
cardiac
lung
lobe
histolog
examin
reveal
system
vascul
affect
lung
figur
panel
spleen
kidney
nasal
epithelium
lymph
node
brain
alveol
lymphaden
hev
antigen
identifi
endotheli
cell
vascular
wall
within
lung
brain
figur
panel
b
nasal
epithelium
lymph
node
spleen
kidney
liver
myocardium
salivari
gland
pharynx
small
intestin
uteru
ovari
adren
gland
well
myocardi
fiber
glomeruli
viral
rna
fourth
control
hors
detect
nasal
swab
collect
postchalleng
day
tabl
summar
tabl
also
blood
collect
immedi
onset
fever
onset
fever
develop
clinic
sign
ill
hev
rna
also
detect
oral
swab
sampl
day
euthanasia
genom
detect
oral
nasal
swab
sampl
blood
rectal
swab
urin
sampl
howev
viru
reisol
sampl
collect
postmortem
examin
viral
rna
detect
tissu
sampl
postmortem
examin
except
cerebrospin
fluid
reisol
viru
attempt
tissu
hev
recov
lung
submandibular
lymph
node
small
intestin
larg
intestin
adren
gland
seri
vaccin
efficaci
studi
hors
immun
hevsg
glycoprotein
expos
otherwis
lethal
dose
hev
oronas
rout
studi
also
includ
pathogen
control
viru
inoculum
first
pathogen
control
fourth
control
hors
describ
togeth
histor
data
gather
hors
follow
exposur
hev
equival
experiment
condit
data
hors
complet
requir
australian
pesticid
veterinari
medicin
author
defin
hors
infect
model
subsequ
studi
guinea
pig
ferret
use
pathogen
control
maxim
number
vaccin
hors
could
accommod
facil
anim
duli
display
sign
lesion
tissu
antigen
viral
genom
distribut
viru
reisol
data
consist
acut
hev
infect
contrast
unvaccin
control
hors
vaccin
hors
remain
clinic
healthi
observ
period
exposur
hev
follow
elect
euthanasia
time
predict
peak
viral
replic
gross
histolog
evid
hev
infect
vaccin
hors
tissu
examin
neg
viral
antigen
immunohistochemistri
viral
genom
recov
tissu
includ
nasal
turbin
pharynx
guttur
pouch
tabl
vaccin
hors
viral
rna
detect
daili
nasal
oral
rectal
swab
specimen
blood
urin
fece
sampl
collect
euthanasia
viru
reisol
clinic
sampl
hors
expos
hev
month
complet
vaccin
cours
low
viral
gene
copi
number
detect
nasal
swab
sampl
collect
postchalleng
day
figur
find
consist
selflimit
local
replic
viru
reisol
sampl
serum
neutral
titer
hev
challeng
rang
hors
challeng
day
second
vaccin
hors
challeng
month
second
vaccin
tabl
time
euthanasia
rise
antibodi
titer
detect
vaccin
hors
follow
exposur
hev
formal
launch
hev
hors
vaccin
novemb
repres
culmin
multipl
studi
conduct
sever
anim
infect
model
cours
mani
year
studi
use
nipah
viru
cat
monkey
hev
ferret
provid
strong
evid
hevsg
glycoprotein
vaccin
could
prevent
diseas
often
infect
anim
expos
otherwis
lethal
dose
nipah
viru
hev
evid
lowlevel
viru
replic
occur
secret
transient
unaccompani
develop
clinic
ill
viru
isol
secret
henipaviru
surfaceexpress
g
glycoprotein
critic
role
initi
infect
bind
receptor
host
cell
antibodi
direct
protein
neutral
viru
earlier
report
shown
passiv
immunotherapi
antibodi
g
f
glycoprotein
hev
nipah
viru
alon
prevent
fulmin
diseas
g
human
monoclon
antibodi
prevent
nipah
viru
diseas
ferret
hev
infect
african
green
monkey
f
g
monoclon
polyclon
antibodi
prevent
hev
nipah
viru
diseas
hamster
thu
like
seen
paramyxovirus
virem
infect
phase
eg
measl
mump
antibodi
g
f
glycoprotein
play
major
role
protect
provid
hevsg
glycoprotein
vaccin
studi
report
show
dose
commerci
formul
hevsg
glycoprotein
vaccin
prevent
infect
hors
expos
hev
least
day
second
vaccin
dose
find
contrast
unvaccin
control
hors
similar
result
obtain
hors
expos
hev
month
vaccin
third
hors
also
remain
clinic
healthi
evid
hev
replic
limit
lowlevel
transient
detect
viral
genom
viru
nasal
caviti
assess
field
signific
observ
follow
must
note
experiment
hors
expos
consider
higher
level
hev
recov
fli
fox
higher
level
viral
genom
routin
found
nasal
secret
nonimmun
hors
human
infect
acquir
anim
clinic
diseas
develop
reason
suggest
higher
transmiss
risk
clearli
associ
hors
consequ
increas
viral
load
also
ill
clinic
ill
hors
promot
increas
contact
diagnost
investig
administr
nurs
care
conclud
level
pattern
viru
replic
vaccin
hors
meet
epidemiolog
criteria
present
associ
transmiss
infect
human
previou
henipaviru
vaccin
efficaci
studi
cat
ferret
neutral
antibodi
titer
shown
protect
develop
clinic
diseas
hors
efficaci
studi
hors
prechalleng
antibodi
titer
similarli
protect
clinic
ill
howev
caution
correl
antibodi
titer
time
exposur
viru
level
subsequ
protect
infect
diseas
unlik
linear
possibl
anim
even
lower
titer
epidemiolog
meaning
protect
hev
exposur
occur
field
least
stimul
immunolog
memori
addit
studi
assess
durat
protect
plan
outcom
inform
recommend
regard
booster
vaccin
expect
initi
uptak
hevsg
glycoprotein
vaccin
strongest
area
highest
perceiv
risk
hev
infect
name
coastal
queensland
australia
region
hev
infect
hors
report
understand
uncertainti
regard
valu
vaccin
part
hors
prevent
health
program
reluct
vaccin
hors
hev
base
assess
risk
probabl
exacerb
sever
factor
includ
novelti
vaccin
rollout
process
australian
hors
industri
mistaken
percept
fasttrack
vaccin
releas
involv
overlook
key
safeti
efficaci
issu
lack
publish
data
safeti
pregnant
mare
reluct
certain
industri
sector
vaccin
import
restrict
hevseroposit
hors
cost
although
like
barrier
diminish
time
experi
may
assist
develop
road
map
guid
futur
releas
vaccin
pathogen
associ
highli
sporad
diseas
event
decis
vaccin
hand
person
vaccin
design
protect
sever
recent
emerg
zoonot
virus
includ
hev
nipah
ebola
marburg
virus
classifi
agent
abil
caus
sever
ill
death
human
effect
vaccin
postexposur
treatment
protect
diseas
caus
vaccin
hev
equivac
hev
commerci
deploy
vaccin
develop
agent
licens
treatment
henipaviru
infect
develop
vaccin
agent
use
human
requir
us
food
drug
administr
implement
anim
rule
requir
vaccin
first
test
efficaci
least
anim
model
veterinari
vaccin
equivac
hev
need
meet
requir
cheaper
faster
produc
vaccin
intend
human
use
time
vaccin
expect
provid
substanti
health
benefit
human
vaccin
encapsul
spirit
one
health
approach
term
interconnected
human
anim
health
also
respect
environment
health
one
consequ
recent
hev
outbreak
move
erad
bat
popul
despit
crucial
environment
role
pollin
reduct
insect
popul
success
deploy
hev
vaccin
target
reduct
risk
acut
diseas
event
hors
human
help
reduc
current
momentum
toward
set
control
polici
potenti
advers
effect
environ
furthermor
increas
evid
henipavirus
henipalik
virus
bat
area
rais
possibl
futur
henipaviru
outbreak
current
hevsg
glycoprotein
vaccin
technolog
provid
platform
rapid
develop
relat
vaccin
counter
futur
emerg
threat
